Celyad Oncology SA
CYADNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CYAD. That does not mean none is planned.
Get an email about CYAD's next catalysts
Track Celyad Oncology (CYAD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
C3BS-CQR-1 | Phase 3 | Heart Failure | - | - |
C-Cure | Phase 3 | Heart Failure Class II or III | - | - |
NKR-2 | Phase 2 | AML | - | - |
Heart Failure
2 drugs in this indication
Heart Failure Class II or III
1 drug in this indication
AML
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Celyad Oncology SA's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Celyad Oncology SA's (CYAD) pipeline across Phase 3, Phase 2. Its lead program is C-Cure (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celyad Oncology SA's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Celyad Oncology SA (CYAD) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CYAD biotech catalysts?→
Add CYAD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celyad Oncology SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.